Previous 10 | Next 10 |
--News Direct-- The cancer experience can be highly emotional. However, prioritizing self-care may help cancer patients cope throughout their journeys. During National Wellness Month, check out these tips to make self-care a priority both during and after treatment. ...
--News Direct-- We are excited to announce we have been nominated to receive an award recognizing our support for the mental health and well-being of our employees from Ibec ! We look forward to joining the other finalists at TheKeepWell Awards on Thursday, Sept 2. h...
Alkermes plc (NASDAQ:ALKS) traded at a new 52-week high today of $29.02. Approximately 160,000 shares have changed hands today, as compared to an average 30-day volume of 1.5 million shares. Alkermes plc has overhead space with shares priced $28.80, or 43.0% below the average consensus a...
The FDA has granted Fast Track designation to nemvaleukin alfa (nemvaleukin), a treatment of mucosal melanoma developed by Alkermes Plc (ALKS), reports John McCamant, biotech expert and editor of The Medical technology Stock Letter. For further details see: Alkermes- On the "Fast Track"...
Shares of Alkermes plc (NASDAQ:ALKS) traded at a new 52-week high today of $28.69. Approximately 160,000 shares have changed hands today, as compared to an average 30-day volume of 2.2 million shares. Alkermes PLC is a fully integrated global biotechnology company that applies its propri...
Alkermes plc (NASDAQ:ALKS) traded at a new 52-week high today of $28.40. So far today approximately 160,000 shares have been exchanged, as compared to an average 30-day volume of 2.2 million shares. Over the past year, Alkermes plc has traded in a range of $15.35 to $28.40 and is now at ...
Alkermes (NASDAQ:ALKS) announces that the U.S. FDA has granted Fast Track designation to nemvaleukin alfa (nemvaleukin) for the treatment of mucosal melanoma. Fast Track is an FDA process designed to facilitate the development and expedite the review of potential therapies that seek to t...
Alkermes Receives FDA Fast Track Designation for Nemvaleukin Alfa for the Treatment of Mucosal Melanoma PR Newswire DUBLIN , Aug. 2, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that the U.S. Food and Drug Administration (FDA) has granted ...
Alkermes plc (NASDAQ:ALKS) traded today at a new 52-week high of $26.00. Approximately 160,000 shares have changed hands today, as compared to an average 30-day volume of 2.1 million shares. Alkermes plc share prices have moved between a 52-week high of $26.00 and a 52-week low of $15.35...
Image source: The Motley Fool. Alkermes plc (NASDAQ: ALKS) Q2 2021 Earnings Call Jul 28, 2021 , 8:00 a.m. ET Operator Continue reading For further details see: Alkermes plc (ALKS) Q2 2021 Earnings Call Transcript
News, Short Squeeze, Breakout and More Instantly...
Alkermes to Report Second Quarter Financial Results on July 24, 2024 PR Newswire DUBLIN , July 17, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET ( 1:00 p.m. BST ) on Wednesday, ...
2024-06-29 16:16:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-19 17:24:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...